Cargando…

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer

Triple negative breast cancers exhibit very aggressive features and poor patient outcomes. These tumors are enriched in cancer stem cells and exhibit resistance to most treatments and chemotherapy. In this study, we found the cyclin-dependent kinase (CDK4) to act as a cancer stem cell regulator and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Meiou, Zhang, Chenjing, Ali, Ayad, Hong, Xinyuan, Tian, Jun, Lo, Chieh, Fils-Aimé, Nadège, Burgos, Sergio A., Ali, Suhad, Lebrun, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069501/ https://www.ncbi.nlm.nih.gov/pubmed/27759034 http://dx.doi.org/10.1038/srep35383

Ejemplares similares

Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer
por: Tian, Jun, et al.
Publicado: (2017)

Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes
por: Guo, Jimin, et al.
Publicado: (2014)

Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2013)

Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2017)

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance
por: Yan, Gang, et al.
Publicado: (2023)

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
por: Tian, Jun, et al.
Publicado: (2018)

TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity
por: Yan, Gang, et al.
Publicado: (2021)

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
por: Dai, Meiou, et al.
Publicado: (2021)

A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2012)

Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2017)

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy
por: López-Ozuna, Vanessa M., et al.
Publicado: (2016)

Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis
por: Shams, Anwar, et al.
Publicado: (2021)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer
por: Ali, Suhad, et al.
Publicado: (2022)

CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target: Role of CPSF6 in Breast Cancer
por: Binothman, Najat, et al.
Publicado: (2017)

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
por: Brisard, Daphne, et al.
Publicado: (2018)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
por: Li, Xiao, et al.
Publicado: (2022)

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
por: Beykou, Melina, et al.
Publicado: (2022)

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
por: Fassl, Anne, et al.
Publicado: (2020)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
por: Cheung, Anthony, et al.
Publicado: (2022)

Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis
por: Han, Zhitao, et al.
Publicado: (2023)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
por: Sang, Xiaoye, et al.
Publicado: (2022)

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
por: Schedin, Troy B., et al.
Publicado: (2018)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome
por: Hachim, Ibrahim Y., et al.
Publicado: (2019)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

LEM Domain Containing 1 Acts as a Novel Oncogene and Therapeutic Target for Triple-Negative Breast Cancer
por: Li, Xiangling, et al.
Publicado: (2023)

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
por: Tang, Lin, et al.
Publicado: (2020)

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2020)

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer
por: Cheng, Sha-Sha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fvab4hcfqh0sr2fatkvmci5rgn